REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Radical -xh Acid, Or Anhydride, Acid Halide Or Salt Thereof (x Is Chalcogen) Doai > Carboxylic Acid, Percarboxylic Acid, Or Salt Thereof (e.g., Peracetic Acid, Etc.) > Higher Fatty Acid Or Salt Thereof > Carbon To Carbon Unsaturation Carbon To Carbon UnsaturationCarbon To Carbon Unsaturation patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/04/07 - 20070004802 - Method for treating renal disease A method for preventing and treating a renal disorder in a human or non-human animal is disclosed. The method involves administering 20-HETE or a 20-HETE agonist to the human or non-human animal in an amount sufficient to prevent or treat the renal disorder. Further disclosed is a method for preventing ... 12/14/06 - 20060281815 - Conjugated linolenic acids and methods of preparation and purification and uses thereof This invention relates to a new conjugated linoleic acids, a process for preparation thereof and method of use. Thus this invention is concerned with the preparation and purification of conjugated linoleic acids from materials rich in alpha or gamma linoleic acids. The reaction produces a mixture containing a 1:1 ratio ... 12/14/06 - 20060281814 - Conjugated linolenic acids and methods for commerical preparation and purification A method for the preparation and purification of conjugated linolenic acids is described. The method comprises blending a mixture of vegetable oils and or fats including various concentrations of alpha or gamma and or both linolenic acids with a base. The method transforms approximately over two thirds of α-linolenic acid ... 11/30/06 - 20060270739 - Synergistic effects of docosahexaenoic acid (dha) and carotenoid absorption on macular pigmentation The present invention provides compositions and methods for increasing the absorption of dietary carotenoids in humans. The methods and compositions of the invention can used to increase the concentration of retinal lutein and zeaxanthin, thereby preventing the onset and/or slowing the progression of macular degeneration. Pharmaceutical compositions comprising a therapeutically ... 11/09/06 - 20060252833 - Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA ... 10/12/06 - 20060229366 - Method for preventing or treating respiratory infections in infants The present invention is directed to a novel method for preventing or treating respiratory infections in infants. The method comprises administration of a therapeutically effective amount of DHA and ARA to the infant. ... 08/24/06 - 20060189692 - Novel anti-proliferative pharmaceutical composition The use of urocanic acid or another pharmaceutically acceptable agent being able to acidify the cell cytoplasm for the manufacture of a pharmaceutical composition useful for causing inhibition or halting of transformed or non-transformed cell proliferation in a person or an animal, where an effective amount of the agent is ... 08/24/06 - 20060189691 - Use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person The use of urocanic acid or another pharmaceutically acceptable agent being able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing inhibition or halting of transformed or non-transformed cell proliferation in a person or an animal, where an effective amount of the agent is ... 08/10/06 - 20060178436 - Use of docosahexanoic acid as active substance for the treatment of lipodystrophy Use of an extract of animal, plant or microorganism produced origin comprising docosahexaenoic acid as active substance for the manufacture of a medicament for the treatment of lipodystrophy in a mammal. Said treatment is effective and overcomes the disadvantages of current lipodystrophy treatments in HIV infected patients. ... 08/03/06 - 20060173077 - Surgical method An irrigation technique that can be used to increase the flow of fluid through the trabecular meshwork and to deliver a therapeutic agent or compound directly into the trabecular meshwork. Pulses of relatively high pressure irrigating balanced salt solution containing a therapeutic agent or compound can be directed at the ... 07/20/06 - 20060160898 - Method of using catalpic acid to treat and prevent type 2 diabetes and associated disorders A method of treating and preventing type 2 diabetes and obesity an animal, including mammals and humans, in which a therapeutically effective amount of catalpic acid to the animal is administered orally or parentally. ... 06/29/06 - 20060142391 - Ppargamma-activating pharmaceutical composition The present invention relates to PPARγ-activating pharmaceutical compositions comprising a hydroxylated derivative of a C20-22 polyunsaturated fatty acid or a pharmaceutically acceptable salt thereof, preferably PPARγ-activating pharmaceutical compositions containing a hydroxylated derivative of docosahexaenoic acid (DHA) or a hydroxylated derivative of eicosapentaenoic acid (EPA) or a pharmaceutically acceptable salt thereof, ... 06/29/06 - 20060142390 - Treatment for severe melancholic depression Methods for treating severe melancholic depression, comprising administering, to a subject, a preparation comprising EPA, or metabolite(s) thereof. ... 06/15/06 - 20060128804 - Novel approach to antimicrobial host defense with molecular shields with epa and dha analogs Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. Various BPI inducing agents include icosapentanoic acid (EPA) analogs and docosahexaenoic acid (DHA) analogs. ... 05/18/06 - 20060106108 - Method for scavenging radicals with urocanic acid, derivatives and analogues The invention relates to antioxidants or radical scavengers and their reaction products. The invention provides compounds and compositions for use in methods for scavenging radicals or for modulating the immune response comprising urocanic acid or salts, derivatives, functional equivalents and analogues thereof. ... 05/11/06 - 20060100279 - Production of dha in microalgae in low ph medium Methods for production of highly unsaturated fatty acids by marine microorganisms, including the heterotrophic marine dinoflagellate Crypthecodinium, using low levels of chloride ion are disclosed. Specifically, methods of increasing production of highly unsaturated fatty acids by marine microorganisms while growing in low chloride media by manipulating sodium ion and potassium ... 05/04/06 - 20060094784 - Tgf-alpha expression inhibitors An inhibitor against TGF-α expression and an inhibitor against transformation of a hepatitis and/or cirrhosis cell which comprise as an active ingredient a polyprenyl compound such as a polyprenyl carboxylic acid (for example, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid). The inhibitor can be used as an inhibitor against onset, recurrence (second oncogenesis), and malignant ... 03/30/06 - 20060069159 - Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical ... 03/30/06 - 20060069158 - Lipoxin compounds and their use in treating cell proliferative disorders Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed. ... 03/23/06 - 20060063838 - Activators of peroxisome proliferator-activated receptors Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient. ... 03/23/06 - 20060063837 - Stabilized leukotriene b4 (ltb4) agent pharmaceutical formulation The present invention relates to a novel pharmaceutical formulation comprising an LTB4 agent at an alkaline pH effective to stabilize the LTB4 agent and provide a formulation with an increased shelf-life. The formulation of the present invention has an increased shelf-life of at least 24 months. ... 03/23/06 - 20060063836 - Method for treating renal disease A method for preventing and treating a renal disorder in a human or non-human animal is disclosed. The method involves administering 20-HETE or a 20-HETE agonist to the human or non-human animal in an amount sufficient to prevent or treat the renal disorder. ... 02/16/06 - 20060035974 - Linoleic acid active agents for enhancing probability of becoming pregnant The present invention is directed to a methods and compositions for enhancing the probability that a subject will become pregnant. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a linoleic acid active agent, e.g., linoleic acid, a polyunsaturated fatty acid analog thereof, etc. ... 02/16/06 - 20060035973 - Pharmaceutical composition for intracellular acidification with cis-urocanic A pharmaceutically acceptable agent able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing immunosuppression in a person or animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal, and where the agent is ... 02/02/06 - 20060025479 - Agents with leukotriene b4-like antiviral (enveloped rna) activities The present invention relates to the use of the antiviral activity of exogenous leukotriene B4 (LTB4), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal enveloped RNA viruses. The human and animal enveloped RNA viruses are RNA viruses, such as togaviridae, orthomyxoviridae, paramyxoviridae, ... 01/26/06 - 20060020031 - Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration, ... 01/12/06 - 20060009522 - Compositions and methods for treating eye disorders and conditions The present invention relates to compositions comprising omega-6 and/or omega-3 fatty acids and uses thereof. The present invention also relates to methods of treatment using such compositions. ... 01/05/06 - 20060004100 - Method of improving animal tissue quality by supplementing the animal diet with oleic acid and selected tocols A novel method for improving the meat quality of an animal is provided. The method comprises feeding the animal a diet supplemented with oleic acid and selected tocols in amounts effective to improve the meat quality. The method may be practiced on non-ruminants and ruminants. ... 12/22/05 - 20050282897 - Methods and compositions for treating diabetes Methods of treating diabetes in an animal and food compositions useful for treating diabetes are described. In one aspect of the invention, the method includes treating the animal with a therapeutically effective amount of CLA including 9,11-octadecadienoic acid and 10,12-octadecadienoic acid, isomers thereof, esters thereof, salts thereof or mixtures thereof. ... 12/01/05 - 20050267212 - Omega-3 fatty acids in the treatment of depression The present invention is directed to a method of treating patients with major depression by administering omega-3 fatty acids. These may be administered in a substantially purified form, as part of a pharmaceutical composition, or as part of a larger molecule, e.g., a triacylglycerol, which releases free fatty acid after ... 12/01/05 - 20050267211 - Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense The use of leukotrienes and other products of the 5-lipoxygenase pathway to enhance bacterial defense and treat infections is described. The products are especially useful when administered to the lungs for the treatment of pneumonia and other lower respiratory tract infections. The products may be administered for treatment or prophylactic ... 11/17/05 - 20050256197 - Methods and compositions for facilitating metabolic control The present invention provides methods for facilitating metabolic control in a subject by decreasing the level of Il-1β in the GCF. The present invention further provides methods for decreasing the level of circulating TNF in a subject. Also provided are uses of anti-inflammatory agents in these methods. ... 11/03/05 - 20050245612 - Pharmaceutical compositions for metabolic insufficiencies Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof. ... 10/27/05 - 20050239889 - In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration The invention relates to the in vivo release of endogenous anti-microbial mediators using leukotriene B4 administration. The present invention furthermore relates to the use of leukotriene B4 for the treatment and/or prophylaxis of diseases that are positively influenced by such anti-microbial mediators. ... 10/13/05 - 20050228047 - Trihydroxy polyunsaturated eicosanoid derivatives The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for ... 10/06/05 - 20050222259 - Methods of activating ppar-alpha nuclear receptors in mammals The use of a composition comprising an unsaturated fatty acid which activates the nuclear receptor PPAR-alpha for the manufacture of a dietary supplement, a functional food, or a medicament for reducing appetite or food intake is disclosed. The preferred substances are conjugated fatty acids especially conjugated linoleic acid. ... 09/29/05 - 20050215641 - Compositions comprising reverse isomers of conjugated linoleic acid The present invention relates to the field of human and animal nutrition, and in particular to certain novel compositions of conjugated linoleic acids (CLA). In particular, the present invention relates to CLA compositions comprising the c10,t12, c10,c12, t9,c11 and c9,c11 isomers of conjugated linoleic acid. ... 09/29/05 - 20050215640 - Hmb compositions and uses thereof The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added ... 09/29/05 - 20050215639 - Disinfectant with activity against hepatitis b virus A composition and a method of using the composition as a disinfectant for inactivating the hepatitis B virus. The composition is contains at least one alkylamine and/or at least one quaternary ammonium compound, and at least one fatty acid RCOOH and/or a salt thereof, where R is a group having ... 09/22/05 - 20050209329 - Potentiation of therapeutic effects of fatty acids The oral administration of an essential fatty acid, preferably eicosapentaenoic acid, at a defined purity together with an inhibitor of COX-1 or COX-2 or LOX or one or more of the FACL enzymes gives improved therapeutic results over administration of the fatty acid alone. ... 09/01/05 - 20050192352 - Method for decreasing cartilage damage in dogs A method for modulating enzymatic degradation of articular cartilage in a dog comprises administering to the dog an enzymatic degradation modulating effective amount of eicosapentaenoic acid (EPA), for example as a component of a food composition. By practice of the method in a dog having arthritis, mobility of the dog ... 07/28/05 - 20050165105 - Method of using punicic acid to enhance immune response and prevent metabolic disorders Disclosed is a method of enhancing the immune response of an animal, including mammals and humans, to prevent or ameliorate immunoinflammatory diseases such as Inflammatory Bowel Disease, increase immune system development, maintain or increase CD4+ and CD8+ T lymphocyte levels, increase immune function, increase immune response against viruses and prevent ... 07/21/05 - 20050159486 - Methods and compositions for the attenuation and/or prevention of stress/catabolic responses Methods and compositions for treating metabolic stress are provided. The method comprises the steps of administering a therapeutically effective amount of conjugated linoleic acid. ... 07/14/05 - 20050154059 - Method of treating type iii hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid A method for treating diseases and conditions caused by type III hypersensitive reactions in a human or non-human animal is disclosed. The method involves administering to the animal a conjugated linoleic acid (CLA) or a substance which can be converted to CLA in the animal in an amount effective to ... 07/07/05 - 20050148668 - Lipoxin compounds and their use in treating cell proliferative disorders Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed. ... 06/30/05 - 20050143465 - Avian appeasing pheromones to decrease stress, anxiety and aggressiveness Compositions comprising a mixture of fatty acids or derivatives thereof derived from secretions of the uropygial glands of birds are disclosed. This composition, named an avian appeasing pheromone, can be used to decrease stress, anxiety and agressiveness in birds. ... ### FreshPatents.com Support |